These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Exploiting replication gaps for cancer therapy. Cong K; Cantor SB Mol Cell; 2022 Jul; 82(13):2363-2369. PubMed ID: 35568026 [TBL] [Abstract][Full Text] [Related]
5. DNA repair and cell cycle checkpoint defects in a mouse model of 'BRCAness' are partially rescued by 53BP1 deletion. Misenko SM; Patel DS; Her J; Bunting SF Cell Cycle; 2018; 17(7):881-891. PubMed ID: 29620483 [TBL] [Abstract][Full Text] [Related]
6. Setting a diagnostic benchmark for tumor BRCA testing: detection of BRCA1 and BRCA2 large genomic rearrangements in FFPE tissue - A pilot study. Valtcheva N; Nguyen-Sträuli BD; Wagner U; Freiberger SN; Varga Z; Britschgi C; Dedes KJ; Rechsteiner MP Exp Mol Pathol; 2021 Dec; 123():104705. PubMed ID: 34637782 [TBL] [Abstract][Full Text] [Related]
7. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. Ashworth A J Clin Oncol; 2008 Aug; 26(22):3785-90. PubMed ID: 18591545 [TBL] [Abstract][Full Text] [Related]
8. BRCAness revisited. Lord CJ; Ashworth A Nat Rev Cancer; 2016 Feb; 16(2):110-20. PubMed ID: 26775620 [TBL] [Abstract][Full Text] [Related]
9. A Novel Mechanism to Induce BRCAness in Cancer Cells. Cai C Cancer Res; 2020 Jul; 80(14):2977-2978. PubMed ID: 32669350 [TBL] [Abstract][Full Text] [Related]
10. Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice. van de Ven M; van der Burg E; van der Gulden H; Klarenbeek S; Bouwman P; Jonkers J J Pathol; 2017 Mar; 241(4):511-521. PubMed ID: 27943283 [TBL] [Abstract][Full Text] [Related]
11. Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer. Sunada S; Nakanishi A; Miki Y Cancer Sci; 2018 Apr; 109(4):893-899. PubMed ID: 29427345 [TBL] [Abstract][Full Text] [Related]
12. Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures. Bodily WR; Shirts BH; Walsh T; Gulsuner S; King MC; Parker A; Roosan M; Piccolo SR PLoS One; 2020; 15(9):e0239197. PubMed ID: 32997669 [TBL] [Abstract][Full Text] [Related]
13. Targeting DNA repair and replication stress in the treatment of ovarian cancer. Murai J Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177 [TBL] [Abstract][Full Text] [Related]
14. Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review. Chalasani P; Livingston R Oncologist; 2013; 18(8):909-16. PubMed ID: 23881989 [TBL] [Abstract][Full Text] [Related]
15. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. Cerrato A; Morra F; Celetti A J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198 [TBL] [Abstract][Full Text] [Related]
16. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides Voutsadakis IA; Stravodimou A Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic exploitation of tumor cell defects in homologous recombination. Powell SN; Kachnic LA Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729 [TBL] [Abstract][Full Text] [Related]
18. Distinct roles of RAD52 and POLQ in chromosomal break repair and replication stress response. Kelso AA; Lopezcolorado FW; Bhargava R; Stark JM PLoS Genet; 2019 Aug; 15(8):e1008319. PubMed ID: 31381562 [TBL] [Abstract][Full Text] [Related]
19. A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance. Tobalina L; Armenia J; Irving E; O'Connor MJ; Forment JV Ann Oncol; 2021 Jan; 32(1):103-112. PubMed ID: 33091561 [TBL] [Abstract][Full Text] [Related]
20. Replication fork stability confers chemoresistance in BRCA-deficient cells. Ray Chaudhuri A; Callen E; Ding X; Gogola E; Duarte AA; Lee JE; Wong N; Lafarga V; Calvo JA; Panzarino NJ; John S; Day A; Crespo AV; Shen B; Starnes LM; de Ruiter JR; Daniel JA; Konstantinopoulos PA; Cortez D; Cantor SB; Fernandez-Capetillo O; Ge K; Jonkers J; Rottenberg S; Sharan SK; Nussenzweig A Nature; 2016 Jul; 535(7612):382-7. PubMed ID: 27443740 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]